Publication Date
| In 2026 | 0 |
| Since 2025 | 0 |
| Since 2022 (last 5 years) | 0 |
| Since 2017 (last 10 years) | 0 |
| Since 2007 (last 20 years) | 1 |
Descriptor
| Behavior Disorders | 3 |
| Drug Therapy | 3 |
| Adolescents | 2 |
| Aggression | 2 |
| Body Weight | 2 |
| Check Lists | 2 |
| Children | 2 |
| Measures (Individuals) | 2 |
| Outcomes of Treatment | 2 |
| Rating Scales | 2 |
| Adults | 1 |
| More ▼ | |
Author
Publication Type
| Journal Articles | 3 |
| Reports - Research | 2 |
| Reports - Evaluative | 1 |
Education Level
Audience
Location
Laws, Policies, & Programs
Assessments and Surveys
| Aberrant Behavior Checklist | 3 |
| Child Behavior Checklist | 1 |
What Works Clearinghouse Rating
Peer reviewed
Direct linkDanov, Stacy E.; Tervo, Raymond; Meyers, Stephanie; Symons, Frank J. – Journal of Mental Health Research in Intellectual Disabilities, 2012
The atypical antipsychotic medication aripiprazole was evaluated using a randomized AB multiple baseline, double-blind, placebo-controlled design for the treatment of severe problem behavior with 4 children with intellectual and developmental disabilities. Functional analysis (FA) was conducted concurrent with the medication evaluation to…
Descriptors: Developmental Disabilities, Rating Scales, Reinforcement, Drug Therapy
Hellings, Jessica A.; Zarcone, Jennifer R.; Reese, R. Matthew; Valdovinos, Maria G.; Marquis, Janet G.; Fleming, Kandace K.; Schroeder, Stephen R. – Journal of Autism and Developmental Disorders, 2006
Risperidone has shown safety and efficacy for aggressive and destructive behaviors in short-term studies. This longer-duration study includes a broad sample. Forty subjects, aged 8-56 years (mean=22), all with mental retardation and 36 with autism spectrum disorders participated in this 22-week crossover study, with 24 weeks of open maintenance…
Descriptors: Drug Therapy, Mental Retardation, Pervasive Developmental Disorders, Children
Handen, Benjamin L.; Hardan, Antonio Y. – Journal of the American Academy of Child & Adolescent Psychiatry, 2006
Objective: Olanzapine, an atypical antipsychotic, has been shown to be efficacious for treatment of psychotic and mood disorders in adults. This prospective, open-label study was conducted to examine the safety and usefulness of olanzapine in treating disruptive behavior disorders in adolescents with subaverage intelligence. Method: Sixteen…
Descriptors: Check Lists, Intelligence, Safety, Moderate Mental Retardation
